The news is a non-stop hype machine for Senti Bio—RMAT designation, completed AML trial enrollment, and a parade of conferences. That's the real story. Technicals are just following the scent, with the 9-period WMA finally crossing above the 21-period, confirming the momentum shift. RSI is neutral, not exhausted. Massive volume on May 1st screams conviction. This is a clear BUY. 🧬🚀

Clinical data dropping in December has this biotech buzzing! 📈 The stock just broke through key resistance with RSI warming up but not overheated. Volume confirms real interest, not just hype. With that FDA orphan drug designation and all these conference appearances, institutions are clearly paying attention. This looks like a BUY before the ASH catalyst. #BiotechRocket

**Analysis:** SNTI’s chart shows wild swings—bullish momentum earlier (RSI near 98! 🚀) collapsed on 4/28 with a sharp drop to $3.64 (bearish engulfing?). Volume spiked, suggesting panic selling or profit-taking. The 9-day EMA crossed below the 21-day, hinting at short-term weakness. RSI at ~55 is neutral now, but the stock feels shaky. News is mixed: positive clinical data vs. shareholder lawsuits. 🚨 **Verdict:** Hold if you’re long-term; wait for stability. Traders might short if it breaks $3.60. High risk, high drama!